Search Results

You are looking at 201 - 210 of 1,146 items for :

  • Refine by Access: All x
Clear All
Full access

Patrick Ross Jr

“Photodynamic therapy (PDT) is not just a palliative treatment,” declared Patrick Ross, Jr, MD, PhD, Director, Division of Thoracic Surgery, The Ohio State University (OSU), Columbus, Ohio. “The real bang for the buck with PDT has got to be

Full access

Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh

untreated and most will die of prostate cancer. 2 The argument for postoperative radiotherapy (RT) is predicated on the assumption that some patients may have residual local disease of a potentially lethal phenotype after surgery and that the delivery of

Full access

Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh

Background Gastric cancer is the fifth most common cancer and second leading cause of cancer-related death globally. 1 Despite improved survival outcomes with multimodality treatment (MMT) compared with surgery alone, nearly half of patients who

Full access

Julie Hallet, Laura Davis, Alyson Mahar, Michail Mavros, Kaitlyn Beyfuss, Ying Liu, Calvin H.L. Law, Craig Earle, and Natalie Coburn

cancer surgery. 1 – 3 This finding has impacted policy through implementation of regionalized care networks for surgery. 4 – 9 Beyond surgical therapy, patient volume for nonsurgical interventions may be important to consider in the delivery of high

Full access

Lindsay J. Collin, Ming Yan, Renjian Jiang, Keerthi Gogineni, Preeti Subhedar, Kevin C. Ward, Jeffrey M. Switchenko, Joseph Lipscomb, Jasmine Miller-Kleinhenz, Mylin A. Torres, Jolinta Lin, and Lauren E. McCullough

women had information available for assigning tumor subtype (ER, the progesterone receptor used to define women as hormone receptor–positive [HR+] or hormone receptor–negative [HR–], and HER2 expression) and had received surgery as part of their local

Full access

R. Michael Tuttle, Douglas W. Ball, David Byrd, Raza A. Dilawari, Gerard M. Doherty, Quan-Yang Duh, Hormoz Ehya, William B. Farrar, Robert I. Haddad, Fouad Kandeel, Richard T. Kloos, Peter Kopp, Dominick M. Lamonica, Thom R. Loree, William M. Lydiatt, Judith C. McCaffrey, John A. Olson Jr., Lee Parks, John A. Ridge, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, and Lori J. Wirth

years and older. 1 – 3 Nodules are even more prevalent when the thyroid gland is examined at autopsy or surgery, or when using ultrasonography, and 50% of these have nodules, which are almost always benign. 2 , 4 New nodules develop at a rate of

Full access

Venkata K. Pokuri, Houman Nourkeyhani, Bodie Betsy, Laurie Herbst, Marcus Sikorski, Edward Spangenthal, Andrew Fabiano, and Saby George

margins were negative. His PSA level was 10 ng/mL before surgery and decreased to less than 0.01 ng/mL after prostatectomy. After surgery he was lost to follow-up. Seven years later, he presented with 3 weeks of gait unsteadiness associated with back pain

Full access

Saber Amin, Michael Baine, Jane Meza, and Chi Lin

, with a median survival time of 4 to 16 months, depending on the primary site. 4 – 6 Current treatment modalities available for the treatment of BMs are surgery, whole-brain radiation therapy (RT), and stereotactic radiosurgery (SRS). 7 , 8 The most

Full access

vivo tumor cellularity. Patients are evaluated for surgery 6 weeks after chemoradiotherapy. Patients with resectable disease proceed to surgery; those with unresectable disease may receive oral vorinostat once daily and oral capecitabine twice daily

Full access

Frank Qian Zhan, Vathani Sharon Packianathan, and Nathalie Charlotte Zeitouni

. Comparison of Mohs micrographic surgery and wide excision in eighty-six patients . Dermatol Surg 1997 ; 23 : 929 – 933 . 66 Boyer JD Zitelli JA Brodland DG D’Angelo G . Local control of primary Merkel cell carcinoma: review of 45 cases treated